Evidence map›Paper›PMID 32892153›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2020

Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.

Jonathan B Wagner, Melissa Ruggiero, J Steven Leeder, Bruno Hagenbuch

Abstract read
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. PharmVar GeneFocus: SLCO1B1.Clinical pharmacology and therapeutics · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jonathan B WagnerWard Family Heart Center (J.B.W.) and Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation (J.B.W., J.S.L.), Children's Mercy, Kansas City, Missouri; Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri (J.B.W., J.S.L.); and Department of Pharmacology, Toxicology, and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas (M.R., B.H.) jbwagner@cmh.edu.
Melissa RuggieroWard Family Heart Center (J.B.W.) and Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation (J.B.W., J.S.L.), Children's Mercy, Kansas City, Missouri; Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri (J.B.W., J.S.L.); and Department of Pharmacology, Toxicology, and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas (M.R., B.H.).
J Steven LeederWard Family Heart Center (J.B.W.) and Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation (J.B.W., J.S.L.), Children's Mercy, Kansas City, Missouri; Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri (J.B.W., J.S.L.); and Department of Pharmacology, Toxicology, and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas (M.R., B.H.).
Bruno HagenbuchWard Family Heart Center (J.B.W.) and Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation (J.B.W., J.S.L.), Children's Mercy, Kansas City, Missouri; Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri (J.B.W., J.S.L.); and Department of Pharmacology, Toxicology, and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas (M.R., B.H.).ORCID 0000-0002-2938-8630

Funding

RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
THE ROLE OF HUMAN PXR IN ANTI-TUBERCULOSIS DRUG-INDUCED LIVER INJURYP20RR021940 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI KLASSEN, CURTIS D · 2006 to 2011
$12.1M
Institutional Career Development CoreKL2TR002367 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI MATTHEW W MOSCONI, NICOLE L NOLLEN · 2017 to 2026
$7.3M
Pilot Grants ProgramP30GM118247 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WEINMAN, STEVEN A · 2016 to 2020
$5.5M
Molecular Characterization of Hepatic Organic Anion Transporting PolypeptidesR01GM077336 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI HAGENBUCH, BRUNO · 2007 to 2019
$3.7M
NCATS NIH HHS KL2 TR002367NCATS NIH HHS UL1 TR002366NCRR NIH HHS P20 RR021940NIGMS NIH HHS P30 GM118247NIGMS NIH HHS R01 GM077336
6 · The paper itself

Abstract

Pravastatin acid (PVA) can be isomerized to its inactive metabolite 3'

Indexed as

Biological Variation, PopulationDose-Response Relationship, DrugHEK293 CellsHumansHydrogen-Ion ConcentrationHydroxymethylglutaryl-CoA Reductase InhibitorsInhibitory Concentration 50Liver-Specific Organic Anion Transporter 1Mutagenesis, Site-DirectedPharmacogenomic VariantsPravastatinStereoisomerismHydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1PravastatinSLCO1B1 protein, human

Identifiers

PMID32892153
PMCPMC7589943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.